OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Cancer is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Editorial Board	278
84 (PB072): Discovery and characterization of potent inhibitors of the RNA editing enzyme ADAR1	264
387 (PB375): Tumor adaptation to PI3K inhibition and its stability increases as a function of time and is overcome by combined inhibiting Bcl2 family proteins	243
405 (PB393): A combination of AURK inhibitor and HDAC inhibitor can restrain Anaplastic Thyroid Cancer aggressiveness: a drug repurposing story	232
250 (PB238): In Vivo Pharmacokinetics, Pharmacodynamics and Anti-tumour Efficacy of EXS74539: A Novel, Reversible LSD1 Inhibitor for Acute Myeloid Leukaemia	162
213 (PB201): MYC Inhibition by OMO-103 Reprograms Tumor Immunity and Enhances Immunotherapy Efficacy in KRAS Mutant NSCLC	161
277 (PB265): Comparative analysis of immune responses in a 3D ex vivo patient tissue platform across diverse cancer types	148
272 (PB260): Establishment and evaluation of radioresistant models from patient derived tissue	146
417 (PB405): Exploring Synthetic Lethality and novel drug combinations in Patient-Derived Cells	145
441 (PB429): GRC 70267, a novel first-generation small molecule degrader of IRAK-M with anti-tumor activity	145
210 (PB198): KRASmulti inhibition and checkpoint targeting therapy show strong combination potential in KRAS wild-type and KRASG12V-driven syngeneic mouse models of pancreatic cancer	141
334 (PB322): PARP1 inhibitor resistant cell line generation and DDR cell panel development	118
310 (PB298): Synergistic Anti-Tumor Effects of the Novel HDAC Inhibitor, ABT-301, with Immune Checkpoint Inhibitors in Colorectal Cancer Through Regulation of Immune Response and Anti-Angiogenesis	110
A-222 Flow cytometry of skin biopsies in CTCL patients during Mogamulizumab treatment	109
A-262 Targeting the hyperactive STAT3/5 Pathway in Cutaneous T-Cell Lymphoma: superior efficacy of multi-kinase inhibitor IQDMA over conventional PUVA therapy	100
A-175 Toward patient-tailored immunotherapy: targeting the TCR idiotype of clonal Sézary lymphomas	99
A-246 Extranodal natural killer/T-cell lymphoma, nasal-type, with extranasal cutaneous presentation - report of 3 cases	94
A-288 Retrospective Clinicopathological Comparative Study between Hypopigmented Mycosis Fungoides and Pityriasis Lichenoides Chronica	90
363 (PB351): Ferrous Iron Reactive (FIRE) delivery of diagnostic or therapeutic agents	87
306 (PB294): OMX-0407 a spectrum selective kinase inhibitor shows preclinical and clinical efficacy in Angiosarcoma, an indication of high unmet medical need	85
71 (PB059): The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: preliminary results from a first-inhuman phase 1/2 study	84
Early versus late response to PD-1-based immunotherapy in metastatic melanoma	83
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma	82
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS	79
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy	78

Response to Letter Re: “A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer”	76
Re: “Evolution of low HER2 expression between early and advanced-stage breast cancer”	72
Real world evidence from a Breast Screening pilot for the underprivileged: Experiences from Bruhat Bengaluru Mahanagara Palike hospitals	72
Characterization of KRAS-driven NSCLC cell lines with diverse mutational landscape and assessment of their response to MYC inhibition	72
Impact of an Online Educational Activity on Oncologists’ Knowledge and Competence Regrading the Optimal Use of Adjuvant Treatment in Breast Cancer	70
Large genome rearrangement of BRCA1/2 in BRCA mutation negative ovarian cancer patients	70
Interactions between BRD4 short, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer	69
Local recurrence of breast cancer after mastectomy. Impact of residual tissue in cancer follow-up	68
Interobserver variation in the assessment of HER2 low expression in breast cancer: can we improve by adjusting criteria? An international interobserver study	67
The ULK1 inhibitor ENV-201 impairs tumor growth in KRAS-driven flank xenografts as a single agent and in combination with the KRAS inhibitor adagrasib	65
Efficiency of textile photodynamic therapy for mycosis fungoides	64
Triple negative breast cancers: Rising menace in the developing world and treatment challenges	64
The Sponsor Acknowledgment and Introduction	63
Non-clinical identification and characterization of KRAS G12D inhibitors	63
The Punjab breast cancer AI-digital project: Implementing Artificial Intelligence-based triaging at scale for population-level screening of breast cancer	63
Unexpectedly high seroprevalance of Kaposi's sarcoma-associated herpesvirus (HHV-8) in patients with stage IV melanoma	62
In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations	62
Ichthyosis associated with immune checkpoint blockade therapy: A novel cutaneous immune-related toxicity	60
Neoadjuvant treatment for breast cancer patients in a Venezuelan breast center. Pathologic complete response: is it worth it?	59
Metabolic profile associated with chemoresistance in ovarian cancer cells using metabolomics	59
External validation and clinical utility assessment of PREDICT v2.2 prognostic model in young, node-negative, systemic treatment-naïve breast cancer patients	59
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies	59
Pagetoid Reticulosis, two case reports and review of the literature	58
Primary Cutaneous Marginal zone B-Cell lymphoma with lymph node involvement. Challenges in differential diagnosis and literature review	58
Histologic Characterization of Sebaceous Glands in Cutaneous T-Cell Lymphoma: Diagnostic and Clinical Correlations	57
Systematic evaluation of label-free protein quantification pipelines in 12 mouse syngeneic models	56
Impact of Oncotype DX Recurrence Score and Nottingham Prognostic Index on adjuvant treatment in patients with axillary lymph node micrometastasis in early breast cancer	56
Overcoming chemoresistance in triple negative breast cancer by bromodomain inhibition	56
The role of a patient with breast cancer in a multidisciplinary team – from making a decision to changing the treatment option	55
Preoperative accelerated partial breast irradiation in locally recurrent breast cancer patients	54
TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy	54
Pharmacological activation of the mitochondrial stress protease OMA1 reveals a therapeutic liability in Diffuse Large B-Cell Lymphoma	54